The treatment of urinary incontinence with Duloxetine

References

• Abrams P, Andersson K E, Brubaker L. Recommendations of the International Scientific Committee: evaluation and treatment of urinary incontinence, pelvic organ prolapsed and faecal incontinence. Incontinence. 3rd ed, P Abrams, L Cardozo, S Khoury, A Wein. Health Publications Ltd, Paris 2005; 1589–1630
   Google Scholar
• Athanasiou S, Chaliha C, Digesu A, Sotiropoulou M, Georgoulias N, Khullar V, et al. The effects of duloxetine on urethral function and sphincter morphology. International Urogynecology Journal 2007; 18: 493–497
   Google Scholar
• Barber M D, Dowsett S A, Mullen K J, Viktrup L. The impact of stress urinary incontinence on sexual activity in women. Cleveland Clinic Journal of Medicine 2005; 72: 225–232
   PubMed Web of Science ®Google Scholar
• Boy S, Reitz A, Wirth B, Karsenty G, Knapp P, Schurch B. Facilitatory neuromodulative effect of duloxetine on urethral sphincter motor neurones in healthy females. European Urology Supplement 2005; 4: 253
   Web of Science ®Google Scholar
• Bump R, Benson J, Yalcin I, Zhao Y, Peng D. Biomechanical and electrophysiological effects of duloxetine in women with stress urinary incontinence. 2004, Available at: http://www.continet.org/publications/2004/pdf/0269.pdf
   Google Scholar
• Bump R, Yalcin I, Voss S. The effect of duloxetine dose escalating and tapering on the incidence of adverse events in women with stress urinary incontinence. Neurourology and Urodynamics 2005; 24: 582
   Google Scholar
• Bump R C, Norton P A, Zinner N R, Yalcin I. Mixed urinary incontinence symptoms: urodynamic findings incontinence severity, and treatment response. Obstetrics and Gynecology 2003; 102: 76–83
   PubMed Web of Science ®Google Scholar
• Cardozo L, Drutz H, Baygani S, Bump R. Pharmacological treatment of women awaiting surgery for stress urinary incontinence. Obstetrics and Gynecology 2004; 104: 511–519
   PubMed Web of Science ®Google Scholar
• Diokno A, Burgio K, Fultz N, Kinchen K, Obenchain R, Bump R. Medical and self care practices reported by women with urinary incontinence. American Journal of Managed Care 2004; 10: 69–78
   PubMed Web of Science ®Google Scholar
• Dmochowski R, Miklos J, Norton P, Zinner N, Yalcin I, Bump R, for the Duloxetine Study Group. Duloxetine versus placebo for the treatment of North American women with stress urinary incontinence. Journal of Urology 2003; 170: 1259–1263
   PubMed Web of Science ®Google Scholar
• Duckett J, Patil A, Aggarwal I. The effect of Duloxetine on urethral sphincter morphology. International Urogynecology Journal 2006; 17: 306–310
   Google Scholar
• Duckett J, Vella M, Kavalakuntla G, Basu M. Tolerability and efficacy of duloxetine in a non trial situation. British Journal of Obstetrics and Gynaecology 2007; 114: 543–547
   Google Scholar
• Duckett J RA, Aggarwal I, Patil A. Duloxetine treatment for women awaiting continence surgery. International Urogynecology Journal 2006; 17: 563–565
   PubMed Web of Science ®Google Scholar
• Fleischmann N, Flisser A, Blaivas J, Panagopoulos G. Sphincteric urinary incontinence: relationship of vesical leak point pressure, urethral mobility and severity of incontinence. Journal of Urology 2003; 169: 999–1002
   PubMedGoogle Scholar
• Fultz N, Burgio K, Diokno A, Kinchen K, Obenchain R, Bump R. Burden of stress urinary incontinence for community-dwelling women. American Journal of Obstetrics and Gynecology 2003; 189: 1275–1282
   PubMed Web of Science ®Google Scholar
• Fultz N, Herzog A. Self-reported social and emotional impact of urinary incontinence. Journal of the American Geriatric Society 2001; 49: 892–899
   PubMed Web of Science ®Google Scholar
• Ghoniem G, van Leeuwen J, Elser D, Freeman R, Zhao Y, Yalcin I, Bump R, for the duloxetine/Pelvic Floor Muscle Training Clinical Trial Group. A randomized controlled trial of duloxetine alone, pelvic floor muscle training alone, combined treatment and no active treatment in women with stress urinary incontinence. Journal of Urology 2005; 173: 1647–1653
   PubMed Web of Science ®Google Scholar
• Rochon P A, Gurwitz J H, Sykora K, Mamdani M, Streiner D L, Garfinkel S, et al. Readers guide to critical appraisal of cohort studies:1 Role and design. British Medical Journal 2005; 330: 895–897
   PubMedGoogle Scholar
• Marriapan P, Ballantyne Z, N'Dow J, Alhasso A. Serotonin and noradrenaline reuptake inhibitors (SNRI) for stress urinary incontinence in adults. Cochrane Database System Reviews 2005; 35: CD004752
   Google Scholar
• Michel M, Peters S L. Role of serotonin and noradrenaline in stress urinary incontinence. BJU International 2004; 94: S23–S30
   PubMedGoogle Scholar
• Millard R, Moore K, Rencken R, Yalcin I, Bump R, for the Duloxetine UI Study Group. Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. BJU International 2004; 93: 311–318
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Women's and Children's Health. NICE Clinical Guideline No. 40: The management of urinary incontinence in women. National Institute for Health and Clinical Excellence, London 2006
   Google Scholar
• Norton P, Zinner N, Yalcin I, Bump R. Duloxetine versus placebo for the treatment of stress urinary incontinence. American Journal of Obstetrics and Gynecology 2002; 187: 40–48
   PubMed Web of Science ®Google Scholar
• Pajoncini C, Costantini F, Guercini F, Bini V, Porena M. Clinical and urodynamic features of intrinsic sphincter deficiency. Neurourology and Urodynamics 2003; 22: 264–268
   PubMed Web of Science ®Google Scholar
• Thor K, Katofiasc M. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. Journal of Pharmacology and Experimental Therapeutics 1995; 274: 1014–1024
   PubMed Web of Science ®Google Scholar
• van Kerrebroeck P, Abrams P, Lange R, Slack M, Wyndele J, Yalcin I, Bump R, for the Duloxetine Urinary Incontinence Study Group. Duloxetine versus placebo in the treatment of European and Canadian women with stress urinary incontinence. British Journal of Obstetrics and Gynaecology 2004; 111: 249–257
   Google Scholar
• van Kerrebroeck P. Duloxetine: an innovative approach for treating stress urinary incontinence. BJU International 2004; 94: S31–S37
   PubMedGoogle Scholar
• Vella M V, Duckett J RA. Duloxetine for mixed incontinence; does it work? Can urodynamics predict outcome?. International Urogynaecology Journal 2007a; 18: S107–S244
   Google Scholar
• Vella M V, Duckett J RA. Duloxetine one year on: are women prepared to take Duloxetine on a long term basis?. International Urogynaecology Journal 2007b; 18: S1–S24
   PubMedGoogle Scholar
• Viktrup L, Bump R. Pharmacological agents used for the treatment of stress urinary incontinence in women. Current Medical Research and Opinion 2003; 19: 485–490
   PubMed Web of Science ®Google Scholar
• Ward K, Hilton P. Prospective multicentre randomised trial of tension-free vaginal tape and colposuspension as primary treatment for stress incontinence. British Medical Journal 2002; 325: 67–70
   PubMed Web of Science ®Google Scholar
• Yalcin I, Bump R C. The effect of previous treatment experience and incontinence severity on the placebo response of stress urinary incontinence. American Journal of Obstetrics and Gynecology 2004; 191: 194–197
   PubMed Web of Science ®Google Scholar